Emerging Stocks Down Under 12 October 2021: Dimerix, Delorean Corporation, HeraMED

Dimerix: Phase-racer

In today's edition of Emerging Stocks Down Under, Melbourne-based Dimerix is a clinical stage biotech company using its lead drug candidate, DMX-200, as a treatment for life-threatening and difficult to treat kidney and lung diseases. With its proprietary technology also proving useful for COVID-19 respiratory illnesses, the company’s lead drug is nearing market approval with multiple Phase 3 clinical trials anticipated this year.   Also in today's edition, a look at renewable energy provider the Delorean Corporation (ASX: DEL) and at-home monitoring and telehealth solutions developer HeraMED (ASX: HMD).  

Click here to read the previous edition of Emerging Stocks Down Under published 5 October 2021

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.

Please register or upgrade your plan to access this content.

Save $$$
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$69
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$59
BILLED ANNUALLY
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks